Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass

International Journal of Obesity

Volumn 37, Issue 11, 2013, Pages 1452-1459

  Dirksen, C ^a,b   Jorgensen N B ^a,b,c   Bojsen Moller K N ^a,b   Kielgast, U ^a   Jacobsen, S H ^a,b   Clausen, T R ^d   Worm, D ^a   Hartmann, B ^b,c   Rehfeld, J F ^a   Damgaard, M ^a   Madsen, J L ^a   Madsbad, S ^a   Holst, J J ^b,c   Hansen, D L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Capital Region   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d NOVO NORDISK A S   (Denmark)

Author keywords

appetite; ghrelin; glucagon like peptide 1; gut hormones; Roux en Y gastric bypass

Indexed keywords

BILE ACID; CHOLECYSTOKININ; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; NEUROTENSIN; PANCREAS POLYPEPTIDE; PEPTIDE YY [3-36];

ADULT; APPETITE; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CALORIMETRY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUNGER; LEAN BODY WEIGHT; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RESTING ENERGY EXPENDITURE; ROUX Y ANASTOMOSIS; SATIETY; STOMACH BYPASS; TEST MEAL; TREATMENT RESPONSE; WEIGHT REDUCTION;

ABSORPTIOMETRY, PHOTON; APPETITE REGULATION; BILE ACIDS AND SALTS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLECYSTOKININ; CROSS-SECTIONAL STUDIES; DUMPING SYNDROME; ENERGY METABOLISM; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; NEUROTENSIN; OBESITY, MORBID; PEPTIDE YY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84887830930     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2013.15     Document Type: Article

References (51)

1. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752.
2. Magro DO, Geloneze B, Delfini R, Pareja BC, Callejas F, Pareja JC. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg 2008; 18: 648-651.
3. Christou NV, Look D, Maclean LD. Weight gain after short-and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 2006; 244: 734-740.
4. Bueter M, Ashrafian H, Le Roux CW. Mechanisms of weight loss after gastric bypass and gastric banding. Obesity Facts 2009; 2: 325-331.
5. Borg CM, Le Roux CW, Ghatei Ma, Bloom SR, Patel a G, Aylwin SJB. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006; 93: 210-215.
6. Le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A et al. Gut hormones as mediators of appetite and weight loss after roux-en-y gastric bypass. Ann Surg 2007; 246: 780-785.
7. Olbers T, Björkman S, Lindroos A, Maleckas A, Lönn L, Sjöström L et al. Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg 2006; 244: 715-722.
8. Halmi KA, Mason E, Falk JR, Stunkard A. Appetitive behavior after gastric bypass for obesity. Int J Obes 1981; 5: 457-464.
9. Laurenius A, Larsson I, Bueter M, Melanson KJ, Bosaeus I, Forslund HB et al. Changes in eating behaviour and meal pattern following Roux-en-Y gastric bypass. Int J Obes 2012; 36: 348-355.
10. Van der Kleij FG, Vecht J, Lamers CB, Masclee AA. Diagnostic value of dumping provocation in patients after gastric surgery. Scand J Gastroenterol 1996; 31: 1162-1166.
11. Sarwer DB, Dilks RJ, West-Smith L. Dietary intake and eating behavior after bar-iatric surgery: threats to weight loss maintenance and strategies for success. Surg Obes Relat Dis 2011; 7: 644-651.
12. Miras A, Jackson R. Gastric bypass surgery for obesity decreases the reward value of a sweet-fat stimulus as assessed in a progressive ratio task. Am J Clin Nutr 2012; 96: 467-473.
13. Burge JC, Schaumburg JZ, Choban PS, DiSilvestro RA, Flancbaum L. Changes in patients' taste acuity after Roux-en-Y gastric bypass for clinically severe obesity. J Am Diet Assoc 1995; 95: 666-670.
14. Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 2012; 22: 1084-1096.
15. Ochner CN, Gibson C, Shanik M, Goel V, Geliebter A. Changes in neurohormonal gut peptides following bariatric surgery. Int J Obes 2011; 35: 153-166.
16. Ybarra J, Bobbioni-Harsch E, Chassot G, Huber O, Morel P, Assimacopoulos-Jeannet F et al. Persistent correlation of ghrelin plasma levels with body mass index both in stable weight conditions and during gastric-bypass-induced weight loss. Obes Surg 2009; 19: 327-331.
17. Sundbom M, Holdstock C, Engström BE, Karlsson FA. Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality? Obes Surg 2007; 17: 304-310.
18. Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg 2012; 22: 740-748.
19. Bueter M, Löwenstein C, Olbers T, Wang M, Cluny NL, Bloom SR et al. Gastric bypass increases energy expenditure in rats. Gastroenterology 2010; 138: 1845-1853.
20. Patti M-E, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009; 17: 1671-1677.
21. Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012; 153: 3613-3619.
22. Jørgensen NB, Jacobsen SH, Dirksen C, Bojsen-Møller KN, Naver L, Hvolris L et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 2012; 303: E122-E131.
23. WEIR JBDB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949; 109: 1-9.
24. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535-539.
25. Rehfeld JF. How to measure cholecystokinin in tissue, plasma and cerebrospinal fluid. Regul Pept 1998; 78: 31-39.
26. Rehfeld JF, Sun G, Christensen T, Hillingsø JG. The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. J Clin Endocrinol Metab 2001; 86: 251-258.
27. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
28. Moŕinigo R, Moizé V, Musri M, Lacy AM, Navarro S, Maŕin JL et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006; 91: 1735-1740.
29. Falkén Y, Hellström PM, Holst JJ, Näslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 2011; 96: 2227-2235.
30. Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, Guven S et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic and Bariatric Surgery Medical Guidelines for Clinical Practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric. Obesity (Silver Spring) 2008; 4: S109-S184.
31. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650-654 2002.
32. Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382-4389.
33. De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner Ea et al. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 2011; 14: 700-706.
34. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146: 5120-5127.
35. Christ-Crain M, Stoeckli R, Ernst A, Morgenthaler NG, Bilz S, Korbonits M et al. Effect of gastric bypass and gastric banding on proneurotensin levels in morbidly obese patients. J Clin Endocrinol Metab 2006; 91: 3544-3547.
36. Holdstock C, Zethelius B, Sundbom M, Karlsson Fa, Edén Engström B. Postprandial changes in gut regulatory peptides in gastric bypass patients. Int J Obes 2008; 32: 1640-1646.
37. Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CaM, Parker HE et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcrip-tional profiling and flow cytometry. Endocrinology 2012; 153: 3054-3065.
38. Rehfeld JF. Cholecystokinin as satiety signal. Int J Obes 1981; 5: 465-469.
39. Patterson M, Bloom SR, Gardiner JV. Ghrelin and appetite control in humans-potential application in the treatment of obesity. Peptides 2011; 32: 2290-2294.
40. Pérez-Romero N, Serra A, Granada ML, Rull M, Alastrué A, Navarro-D́iaz M et al. Effects of two variants of Roux-en-Y Gastric bypass on metabolism behaviour: focus on plasma ghrelin concentrations over a 2-year follow-up. Obes Surg 2010; 20: 600-609.
41. Matzko ME, Argyropoulos G, Wood GC, Chu X, McCarter RJM, Still CD et al. Association of ghrelin receptor promoter polymorphisms with weight loss following Roux-en-Y gastric bypass surgery. Obes Surg 2012; 22: 783-790.
42. Le Roux CW, Patterson M, Vincent RP, Hunt C, Ghatei Ma, Bloom SR. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 2005; 90: 1068-1071.
43. Engström BE, Ohrvall M, Sundbom M, Lind L, Karlsson Fa. Meal suppression of circulating ghrelin is normalized in obese individuals following gastric bypass surgery. Int J Obes 2007; 31: 476-480.
44. Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006; 14: 1553-1561.
45. Schwartz TW, Rehfeld JF, Stadil F, Larson LI, Chance RE, Moon N. Pancreatic-polypeptide response to food in duodenal-ulcer patients before and after vagotomy. Lancet 1976; 1: 1102-1105.
46. Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep 2011; 11: 160-166.
47. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-177.
48. Goldfinea B, Mun EC, Devine E, Bernier R, Baz-Hecht M, Jones DB et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007; 92: 4678-4685.
49. Tamboli Ra, Hossain HA, Marks Pa, Eckhauser AW, Rathmacher Ja, Phillips SE et al. Body composition and energy metabolism following Roux-en-Y gastric bypass surgery. Obesity (Silver Spring) 2010; 18: 1718-1724.
50. Das SK, Roberts SB, McCrory Ma, Hsu LKG, Shikora Sa, Kehayias JJ et al. Long-term changes in energy expenditure and body composition after massive weight loss induced by gastric bypass surgery. Am J Clin Nutr 2003; 78: 22-30.
51. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19.